RCEL · XBRL financial data

AVITA Medical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RCEL's year ends in late December)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	29,232	—	34,421	50,143	64,251	71,610
Cost of revenue	5,949	—	6,041	7,780	9,094	12,794
Gross profit	23,283	—	28,380	42,363	55,157	58,816
Research and development	14,818	—	13,857	20,821	20,360	20,839
General and administrative	22,400	—	23,330	28,334	33,195	27,373
Total operating expenses	51,878	—	59,100	86,446	111,750	101,350
Other operating income (expense)	2,055	—	3,215	1,428	—	—
Operating income (loss)	(26,540)	—	(27,505)	(42,655)	(56,593)	(42,534)
Interest expense	22	—	16	1,143	5,361	5,004
Other income (expense)	—	—	892	8,483	163	(1,038)
Income tax expense (benefit)	38	—	36	66	54	11
Net income (loss)	(26,583)	—	(26,665)	(35,381)	(61,845)	(48,587)
Earnings per share, basic USD per share	1.17	—	1.07	1.40	(2.39)	(1.74)
Earnings per share, diluted USD per share	1.17	—	1.07	1.40	(2.39)	(1.74)
Weighted average shares, basic thousands of shares	22,674	—	25,000	25,331	25,883	27,861
Weighted average shares, diluted thousands of shares	22,674	—	25,000	25,331	25,883	27,861

Fiscal years (RCEL's year ends in late December)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	110,746	55,511	18,164	22,118	14,050	10,243
Marketable securities	—	29,649	61,178	66,939	21,835	7,942
Marketable securities, non-current	—	19,692	6,930	—	—	—
Accounts receivable	3,467	3,118	3,515	7,664	11,786	9,086
Inventory	1,647	2,132	2,125	5,596	7,269	6,926
Prepaid and other current assets	1,333	1,213	1,578	1,659	2,004	1,293
Total current assets	121,330	92,132	87,458	104,006	57,000	35,490
Property and equipment, net	1,458	1,262	1,200	1,877	10,018	8,630
Right-of-use asset	1,480	1,544	851	2,440	3,571	2,899
Total assets	125,501	116,015	98,264	111,640	79,711	56,392
Current portion of long-term debt	—	—	—	—	0	42,984
Total current liabilities	7,390	9,146	10,693	13,199	20,158	62,677
Long-term debt	—	—	—	39,812	42,245	0
Lease liability, non-current	878	918	306	1,702	2,840	2,135
Total liabilities	9,846	11,391	12,967	61,891	74,968	73,042
Accumulated deficit	(221,496)	(235,923)	(262,588)	(297,969)	(359,814)	(408,401)
Total stockholders' equity	115,655	104,624	84,740	49,056	4,499	(16,650)
Total liabilities and equity	125,501	116,015	98,264	111,640	79,711	56,392
Common shares outstanding (cover page) thousands of shares	24,896	24,926	25,296	25,707	26,358	30,632

Fiscal years (RCEL's year ends in late December)

In thousands of dollars	FY 2021Jun 30, 2021	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(26,583)	—	(26,665)	(35,381)	(61,845)	(48,587)
Stock-based compensation	5,664	—	6,998	8,384	13,496	9,519
Depreciation and amortization	715	—	568	632	1,126	2,347
Net cash from operating activities	(25,901)	—	(19,090)	(38,011)	(48,939)	(31,195)
Purchases of property and equipment	894	—	452	1,381	9,171	1,005
Net cash from investing activities	(1,174)	—	(19,332)	1,607	37,363	12,452
Proceeds from issuing common stock	69,106	—	—	—	—	14,792
Proceeds from long-term debt	—	—	—	38,762	—	—
Net cash from financing activities	64,049	—	900	40,374	3,508	14,936
Net change in cash	37,107	—	(37,548)	3,954	(8,068)	(3,807)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026
Picard Medical	38	2,954	(1,352)*	2.3M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Neuronetics	22,106	41,962	not reported	77.7M	—	Q3 FY26 10-QSep 30, 2026
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Sight Sciences	79,753	23,388	(5,663)*	55.1M	14.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.